Stroke:血压对成功再灌注后卒中患者结局的影响

2019-07-19 国际循环编辑部 国际循环

在机械性血栓切除术治疗的患者中,超过2/3的患者可实现成功再灌注。因此,了解血压(BP)对成功再灌注后临床结局的影响非常重要。发表于Stroke的一项研究探讨了入院时血压和成功再灌注后24小时内血压与临床结局的关系。

在机械性血栓切除术治疗的患者中,超过2/3的患者可实现成功再灌注。因此,了解血压(BP)对成功再灌注后临床结局的影响非常重要。发表于Stroke的一项研究探讨了入院时血压和成功再灌注后24小时内血压与临床结局的关系。

研究共计纳入10个综合性卒中中心的1245例患者,平均年龄为(69±14)岁,51%的患者为女性。为确保研究队列的同质性,仅入选手术结束时成功再通的前循环患者。临床结局包括90天改良Rankin量表,症状性脑出血(sICH),死亡率和偏侧颅骨切除术。

结果显示,49%的患者在90天时具有良好的功能结局,4.7%的患者患有sICH。入院收缩压(SBP),平均SBP,最大SBP,SBP SD和SBP范围与sICH高风险相关。此外,较高平均SBP组的患者具有较高的sICH发病率。在行偏侧颅骨切除术的患者中发现类似结果。关于功能结局,平均SBP,最大SBP和SBP范围与良好结局呈负相关(改良Rankin量表评分为0~2)。然而,较差和良好结局组之间SBP参数的差异不显著。

研究表明,成功机械血栓切除术后最初24小时内血压升高与sICH,死亡率和需偏侧颅骨切除术的可能性较高相关。

原始出处:
Mohammad Anadani, Mohamad Y. Orabi, Ali Alawieh,et al.Blood Pressure and Outcome After Mechanical Thrombectomy With Successful Revascularization. Stroke. Jul 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720302, encodeId=05071e2030227, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Apr 28 13:59:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480026, encodeId=6850148002611, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Jul 21 09:59:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026410, encodeId=cdd110264107e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Jul 19 21:59:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369953, encodeId=e8633699530d, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Jul 19 21:02:06 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720302, encodeId=05071e2030227, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Apr 28 13:59:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480026, encodeId=6850148002611, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Jul 21 09:59:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026410, encodeId=cdd110264107e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Jul 19 21:59:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369953, encodeId=e8633699530d, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Jul 19 21:02:06 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720302, encodeId=05071e2030227, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Apr 28 13:59:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480026, encodeId=6850148002611, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Jul 21 09:59:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026410, encodeId=cdd110264107e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Jul 19 21:59:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369953, encodeId=e8633699530d, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Jul 19 21:02:06 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
    2019-07-19 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1720302, encodeId=05071e2030227, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Tue Apr 28 13:59:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480026, encodeId=6850148002611, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Jul 21 09:59:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026410, encodeId=cdd110264107e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Fri Jul 19 21:59:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369953, encodeId=e8633699530d, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Fri Jul 19 21:02:06 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
    2019-07-19 qingfengqishi5

    学习了,学习了

    0

相关资讯

Lancet Diabetes Endo:热量摄入限制与心脏代谢风险研究

中度热量限制显著降低中青年非肥胖人群的多种心脏代谢危险因素

J Rheumatol:系统性红斑狼疮的血压变异性和年龄相关血压模式

SLE中的年龄相关血压模式与一般人群不同。

JACC:青年血压和胆固醇水平升高,增加心血管事件

血压(BP)和胆固醇是心血管疾病(CVD)的主要可改变风险因素,但青年期暴露对晚年CVD风险的影响尚未得到很好的量化。发表于JACC的一项研究,研究者探索评估青年期暴露于风险因素和晚期CVD风险的独立相关性,并考虑了后续的生活暴露。

CSA&TISC2019丨周立新教授:卒中患者的血压管理策略思考

编者按:众所周知,血压管理应贯穿卒中防治的全过程。急性卒中患者的血压应控制在什么水平,不同类型的卒中是否需采取不同血压管理策略及目标水平?如何选择降压治疗的时机、平衡降压治疗的风险与获益?6月29日,在CSA&TISC 2019脑血管危险因素预防与控制专场,北京协和医院周立新教授就临床实践中两大类最常见的卒中类型的血压管理策略作了详细介绍。

Circulation:白藜芦醇矛盾地降血压机制

白藜芦醇是一种天然多酚,具有促进健康和限制疾病的能力,因此人们对了解其治疗作用的机制很感兴趣。白藜芦醇的多酚环能与其他有害氧化剂反应并解毒。虽然白藜芦醇的保护作用通常归因于其抗氧化活性,但近期研究表明这是一种误解。研究人员在分离的大鼠动脉平滑肌细胞中评估白藜芦醇氧化cGMP依赖性PKG1α(蛋白激酶1α)的能力,并通过体外实验、质朴和MRI来研究其作用机制。结果显示,白藜芦醇酚环的氧化矛盾地导致了